OA01.26. Evaluation of tablet hrudayrog chintamani in management of coronary artery disease

PURPOSE: Coronary Artery Disease is forecasted to be the most common cause of death globally, by 2020. The only standard care of treatment (SCT) for CAD i.e. CABG/PTCA is invasive and expensive. There is no established medical management for reversion of CAD except medical maintenance of CAD. We propose cost effective herbo-mineral preparation with the complete protocol, expected to cost US $ 500 against the cost of SCT: US 2000 +; which will avoid CABG/PTCA and the recurrence of CAD in post CABG/PTCA patients. The therapy would be beneficial for the contraindicated conditions of CABG/PTCA. METHOD: This is an open, single arm, prospective study with sample size of 20 patients in pilot study (2years) and 200 in the final study (5 yrs). Established CAD patients in the age group of 15-60, having LVEF >30% are recruited. The patient having Left Main Disease, proximal LAD disease >66%, other cardiac dysfunctions like MR, Left Ventricular Aneurism, VSD, LVESV> 60ml are excluded. Investigations include CAG (Day 0 and after 12 months), 2 D Echo, TMT,(BSL/HbA1c in stable DM2) and RFT/LFT every 4 months. RESULT: Interim analysis reveals major findings including, 1) significant reduction in CA blockage with improvement in TMT, 2DEcho and QOL, 2) statistical data of Dosha predominance in CAD, male to female ratio.3) Ayurvedic etiologies of CAD with prevalence of stress factor in majority of cases, 4) safety data of drugs after prolong administration of Ayurvedic CONCLUSION: Confirmation of reversion of CAD with improvement in QOL, No safety issue (though protocol includes herbomineral preparations), Challenges like recruitment, follow up, salient observations will be discussed in details, It is not a single drug or herbomineral but the complete Ayurvedic protocol proves effective in reversion of Tridoshtmaka disease like CAD.